NASDAQ$LPSN

LivePerson Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

LivePerson's Q1 2023 revenue aligned with expectations, while adjusted EBITDA surpassed guidance. The company divested Kasamba and repurchased a significant portion of convertible notes.

LivePerson's Q1 2023 saw a total revenue of $107.7 million, a 17% decrease compared to the same period last year. The company signed 70 deals, including 20 new and 50 existing customer contracts. Adjusted EBITDA was $(1.3) million, and the company reaffirmed its full-year revenue and adjusted EBITDA guidance.

  • Total revenue for Q1 2023 was $107.7 million, a 17% decrease year-over-year.
  • The company signed 70 deals in Q1, including 20 new and 50 existing customer contracts.
  • Adjusted EBITDA for Q1 2023 was $(1.3) million, compared to $(17.6) million for Q1 2022.
  • LivePerson reaffirmed its full-year 2023 revenue guidance of $394M to $408M and adjusted EBITDA guidance of $15M to $32M.

Headline financials

Total Revenue

$108M

Previous: $130M-17.3%
EPS (adj)

-$0.23

Previous: -$0.86+73.3%
Adjusted EBITDA

-$1.3M

Previous: -$17.6M+92.6%
Capital Expenditures

-$9.63M

Previous: -$13.1M+26.7%
Free Cash Flow

-$27M

Previous: -$78.5M+65.5%
Net Income

-$17.4M

Previous: -$65.4M+73.3%
Operating Income

-$32.7M

Previous: -$65.1M+49.8%
Gross Profit

$64.6M

Previous: $80.6M-19.9%
Cash & Equivalents

$240M

Previous: $481M-50.1%
Total Assets

$958M

Previous: $1.2B-20.5%
Stock-Based Comp

$11.3M

Previous: $31.9M-64.4%

Revenue & EPS history

LivePerson · Revenue · Quarterly

$108M

Q1 2023-17.3%vs Q1 2022
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Revenue by segment

LivePerson · $108M total across 2 segments · Q1 2023

  • Hosted services
    $87.3M
  • Professional services
    $20.3M

Forward guidance

LivePerson is reaffirming its full-year revenue and adjusted EBITDA guidance. For the second quarter, the company expects revenue between $95M and $99M and adjusted EBITDA between $3M and $7M.

Tailwinds

  • Full year revenue guidance range is $394M to $408M.
  • Full-year adjusted EBITDA guidance range of $15M to $32M.
  • Recurring revenue component of total revenue in the second quarter is expected to be approximately 87%, which implies 2% growth sequentially.
  • Sequential improvement in profitability expected for the remainder of the year.
  • Wild Health’s growth in the first quarter was consistent with the expectations set last quarter for its core revenue to double for the full year.

Headwinds

  • Second quarter revenue is expected to be $95M to $99M, a decline of -23% to -20% YoY.
  • Sequential decline in total revenue from the first quarter is due primarily to professional services revenue from the JV that is not expected to continue.
  • Part of the overperformance in the first quarter was due to the timing of certain expenses that we expect to recognize later in the year.
  • Inclusive of Kasamba revenue, guidance range for full year revenue is a decline of -23% to -21% YoY.
  • Normalizing for Kasamba in both periods, our revenue guidance range is a decline of -19% to -16% YoY.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-1.7%

Avg return

Earnings day

-1.7%

Avg return

5 days after

-3.8%

Avg return

30 days after

35%

22 / 62 earnings

Positive

+43.3%

Q1 2020

Best reaction

-56.4%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.9%-19.5%-21.1%
Q4 2025-1.1%-1.5%+1.9%
Q3 2025+12.4%-2.9%+1.3%
Q1 2025+8.1%+12.8%+0.0%
Q4 2024-16.0%-22.7%-38.2%
Q3 2024-25.7%-27.4%-23.1%
Q2 2024-11.6%-10.9%-4.7%
Q1 2024-2.0%+11.9%+10.2%
Q4 2023-50.6%-51.0%-61.1%
Q3 2023-9.0%-7.7%+15.0%
Q2 2023+18.2%+26.4%-1.2%
Q1 2023+27.9%+0.7%-17.4%
Q4 2022-56.4%-60.1%-44.1%
Q3 2022+20.4%+34.7%+12.0%
Q2 2022-17.8%-11.1%-26.5%
Q1 2022-5.4%-6.3%-14.1%
Q4 2021-20.7%+3.0%+4.7%
Q3 2021-5.3%-6.7%-32.3%
Q2 2021-2.5%-3.3%+3.7%
Q1 2021-3.1%-3.5%+1.2%
Q4 2020+9.1%+7.6%-13.5%
Q3 2020-5.5%-3.8%+2.4%
Q2 2020+24.0%+27.1%+17.6%
Q1 2020+43.3%+44.5%+47.6%
Q4 2019-23.3%-26.3%-53.3%
Q3 2019-16.3%-16.1%-9.8%
Q2 2019+3.6%-1.7%+21.9%
Q1 2019-0.8%-0.7%-3.2%
Q4 2018+4.3%+8.9%+7.4%
Q3 2018-7.5%-11.0%-16.7%
Q2 2018+3.9%+3.9%+15.9%
Q1 2018+8.4%+9.3%+17.5%
Q4 2017+15.3%+14.5%+21.3%
Q3 2017-17.9%-16.4%-21.4%
Q2 2017+17.9%+18.3%+11.8%
Q1 2017+22.6%+27.7%+41.5%
Q4 2016-0.7%+4.3%-4.3%
Q3 2016-3.0%+1.2%+0.0%
Q2 2016-15.0%-11.3%+4.4%
Q1 2016-3.5%
Q4 2015-18.8%
Q3 2015-7.9%
Q2 2015+12.3%
Q1 2015-10.3%
Q4 2014-1.1%
Q3 2014+0.7%
Q2 2014+21.8%
Q1 2014-3.0%
Q4 2013-8.0%
Q3 2013+20.8%
Q2 2013+0.7%
Q4 2012-6.1%
Q3 2012-12.5%
Q1 2011+7.7%
Q1 2012+2.1%
Q4 2009-0.4%
Q4 2011-0.4%
Q3 2010-4.2%
Q3 2011-4.2%
Q2 2010-3.5%
Q2 2011-3.5%
Q4 2010-3.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro